Based on the preclinical data, FLT3-ITD+ AML patients with high ITD-AR at diagnosis may respond well to gilteritinib, which currently lacks regulatory approval for newly diagnosed AML with FLT3 mutation. This evidence concerns the gene FLT3 and acute myeloid leukemia.